Maria Lacerca-Allen
Compliance Officer chez AIMMUNE THERAPEUTICS, INC.
Fortune : 6 955 $ au 31/03/2024
Profil
Maria Fabiana Lacerca-Allen is currently the Director at American Red Cross Bay Area, Independent Non-Executive Director at Shield Therapeutics Plc, and Chief Compliance Officer & Senior Vice President at Aimmune Therapeutics, Inc. Her former jobs include Compliance Director-Latin America & Canada at Bristol Myers Squibb Co., Non-Executive Director at Arthrocare Corp., Chief Compliance Officer at Elan Corp.
Plc, and Chief Compliance Officer & Senior Vice President at Mylan, Inc. She has also held the position of Chief Compliance Officer at Mylan Laboratories, Inc. Dr. Lacerca-Allen has a graduate degree from the University of California, Los Angeles and graduate and doctorate degrees from Universidad de Buenos Aires.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
SHIELD THERAPEUTICS PLC
0,03% | 31/12/2022 | 271 886 ( 0,03% ) | 6 955 $ | 31/03/2024 |
Postes actifs de Maria Lacerca-Allen
| Sociétés | Poste | Début |
|---|---|---|
| SHIELD THERAPEUTICS PLC | Director/Board Member | 10/05/2021 |
| AIMMUNE THERAPEUTICS, INC. | Compliance Officer | 01/10/2020 |
| American Red Cross Bay Area | Director/Board Member | - |
Anciens postes connus de Maria Lacerca-Allen
| Sociétés | Poste | Fin |
|---|---|---|
| ARTHROCARE CORPORATION | Director/Board Member | 29/05/2014 |
Elan Corp. Plc
 Elan Corp. Plc Pharmaceuticals: MajorHealth Technology Elan Corp. Plc is a neuroscience focused biotechnology company. The company engages in research, development, and commercial activities for neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease and autoimmune diseases, including multiple sclerosis. It was founded in December 1969 and is headquartered in Dublin, Ireland. | Compliance Officer | 24/04/2014 |
Mylan Laboratories, Inc.
 Mylan Laboratories, Inc. Pharmaceuticals: GenericHealth Technology Mylan Laboratories, Inc. is engaged in developing, licensing, manufacturing, marketing and distributing generic and brand pharmaceutical products. The company manufactures and markets over 140 generic products in approximately 360 product strengths covering over 40 therapeutic categories. The company manufactures products for conditions ranging from angina to arthritis, depression to diabetes, pain to Parkinson's disease and schizophrenia to sleep disorders. The company operates through its three subsidiaries: a) Mylan Pharmaceuticals (Morgantown, West Virginia) is primarily focused on solid oral dose generic pharmaceutical products. b) Mylan Technologies (St. Albans, Vermont) is the pioneer in generic transdermal drug delivery technology and is the producer of generic transdermal patches for the U.S. market. c) UDL Laboratories (Rockford, Illinois) is the number one supplier of unit dose pharmaceuticals to hospitals and other institutions across the United States. The company was incorporated in 1970 and is headquartered in Canonsburg, PA. | General Counsel | 02/10/2007 |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | - |
Mylan, Inc.
 Mylan, Inc. Pharmaceuticals: MajorHealth Technology Mylan, Inc. develops, manufactures, and licenses generic pharmaceuticals. The firm operates its business through two segments: Generics and Specialty. The Generics segment primarily develops, manufactures, sells and distributes generic or branded generic pharmaceutical products in tablet, capsule, injectable or transdermal patch form, as well as API. The Specialty segment engages mainly in the development, manufacture and sale of branded specialty nebulized and injectable products. The company was founded by Milan Puskar and Don Panoz in 1961 and is headquartered in Canonsburg, PA. | General Counsel | - |
Formation de Maria Lacerca-Allen
| University of California, Los Angeles | Graduate Degree |
| Universidad de Buenos Aires | Doctorate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| SHIELD THERAPEUTICS PLC | Health Technology |
| Entreprise privées | 6 |
|---|---|
Elan Corp. Plc
Elan Corp. Plc Pharmaceuticals: MajorHealth Technology Elan Corp. Plc is a neuroscience focused biotechnology company. The company engages in research, development, and commercial activities for neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease and autoimmune diseases, including multiple sclerosis. It was founded in December 1969 and is headquartered in Dublin, Ireland. | Health Technology |
Mylan Laboratories, Inc.
Mylan Laboratories, Inc. Pharmaceuticals: GenericHealth Technology Mylan Laboratories, Inc. is engaged in developing, licensing, manufacturing, marketing and distributing generic and brand pharmaceutical products. The company manufactures and markets over 140 generic products in approximately 360 product strengths covering over 40 therapeutic categories. The company manufactures products for conditions ranging from angina to arthritis, depression to diabetes, pain to Parkinson's disease and schizophrenia to sleep disorders. The company operates through its three subsidiaries: a) Mylan Pharmaceuticals (Morgantown, West Virginia) is primarily focused on solid oral dose generic pharmaceutical products. b) Mylan Technologies (St. Albans, Vermont) is the pioneer in generic transdermal drug delivery technology and is the producer of generic transdermal patches for the U.S. market. c) UDL Laboratories (Rockford, Illinois) is the number one supplier of unit dose pharmaceuticals to hospitals and other institutions across the United States. The company was incorporated in 1970 and is headquartered in Canonsburg, PA. | Health Technology |
Arthrocare Corp.
 Arthrocare Corp. Medical SpecialtiesHealth Technology ArthroCare Corp. manufactures medical devices for cardiovascular, spinal and other medical treatments. The company was founded on April 29, 1993 and is headquartered in Memphis, TN. | Health Technology |
Mylan, Inc.
Mylan, Inc. Pharmaceuticals: MajorHealth Technology Mylan, Inc. develops, manufactures, and licenses generic pharmaceuticals. The firm operates its business through two segments: Generics and Specialty. The Generics segment primarily develops, manufactures, sells and distributes generic or branded generic pharmaceutical products in tablet, capsule, injectable or transdermal patch form, as well as API. The Specialty segment engages mainly in the development, manufacture and sale of branded specialty nebulized and injectable products. The company was founded by Milan Puskar and Don Panoz in 1961 and is headquartered in Canonsburg, PA. | Health Technology |
| American Red Cross Bay Area | |
Aimmune Therapeutics, Inc.
 Aimmune Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of desensitization treatments for peanut and other food allergies. Its portfolio includes the characterized oral desensitization immunotherapy system. The firm product include Palforzia, which is an oral immunotherapy indicated for the mitigation of allergic reactions, including anaphylaxis that may occur with accidental exposure to peanut. The company was founded on June 24, 2011 and is headquartered in Brisbane, CA. | Health Technology |
